ReviewiScience2025
Current evidence and challenges of multitarget anti-angiogenic agents for glioblastoma: Results from clinical trials.
Review in iScience, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Targeting Kinase Signaling in Glioblastoma: Structural Optimization, Blood-Brain Barrier Dynamics and Combinatorial Translational Strategies.International journal of molecular sciences · 2026Review
- Review
- Combining anti-metabolic treatments with the repurposing of eribulin for glioblastoma: a clinical opportunity?Translational cancer research · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is a highly vascularized and aggressive brain tumor with a dismal prognosis. This systematic review critically appraises clinical evidence for multitarget anti-angiogenic agents, which inhibit pathways such as VEGFR, FGFR, and PDGFR. Most supporting data come from small, single-arm phase II trials or retrospective studies. Five challenges are highlighted: (i) translational shortcomings of current preclinical models, (ii) restriction of agent delivery by the blood-brain barrier (BBB), (iii) heterogeneity of tumor endothelial cells (TECs) driving intrinsic and adaptive resistance, (iv) angiogenic escape via vasculogenic mimicry (VM), and (v) a lack of consensus on late-line treatment for recurrent GBM (rGBM). Future research should prioritize robust biomarker development, brain-penetrant agents, strategies tailored to specific TEC subtypes, and disruption of VM to unlock the full therapeutic potential of anti-angiogenic agents in GBM. This review provides an evidence-based foundation and translational research guidance for clinicians and pharmaceutical researchers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.